Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Vascular Endothelial Growth Factor Receptor Inhibitor 100%
• Angiogenesis 66%
• Vascular Endothelial Growth Factor 66%
• Cancer Progression 33%
• Phase II Study 33%
• Carboplatin 33%
• Drug Class 33%
• Paclitaxel 33%
• Chemotherapy Alone 33%
• Vascular Endothelial Growth Factor Receptor (VEGFR) 33%
• Bevacizumab 33%
• Previously Untreated 33%
• Cancer Growth 33%
• Non-squamous Non-small Cell Lung Cancer 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase 100%
• Non Small Cell Lung Cancer 100%
• Vasculotropin Receptor 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Cancer Growth 50%
• Vasculotropin 50%
• Chemotherapy 25%
• Paclitaxel 25%
• Carboplatin 25%
• Bevacizumab 25%